Korea’s Boryung Licenses Hypertension Therapy Kanarb To China’s Harbin Gloria
This article was originally published in PharmAsia News
In its latest deal for the sale of its hypertension Kanarb product outside Korea, Boryung signed a 10-year deal with China from 2018.
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.